Amylyx Pharmaceuticals ($AMLX) Stock Forecast: Up 6.0% Today

What is Amylyx Pharmaceuticals?

Asset Amylyx Pharmaceuticals (NASDAQ: AMLX) is a pharmaceutical company specializing in treatments for neurodegenerative diseases like ALS and Wolfram syndrome. Today, the stock showed a robust bullish movement.

Why is Amylyx Pharmaceuticals going up?

AMLX stock is up 6.0% on Jun 5, 2026 14:16

• Key proposals at the Annual Meeting of Stockholders, including the election of new directors and the ratification of the independent accounting firm, likely boosted investor confidence in the company's governance and strategic direction.
• Analysts' optimism about Amylyx Pharmaceuticals' growth prospects, particularly in the post bariatric hypoglycemia (PBH) and neurodegeneration pipeline, may have attracted investors looking for long-term opportunities in the pharmaceutical industry.
• Progress in the pivotal Phase III LUCIDITY trial for avexitide, alongside potential future revenues and a positive estimated fair value per share, could have contributed to the bullish sentiment surrounding AMLX stock today.

AMLX Price Chart

AMLX Technical Analysis

AMLX News

Amylyx Pharmaceuticals (NASDAQ: AMLX) investors approve directors, auditor and say-on-pay

Amylyx Pharmaceuticals (NASDAQ: AMLX) held its Annual Meeting of Stockholders on June 4, 2026, where investors approved several key proposals. Stockholders elected George Mclean Milne Jr., Ph.D. and Paul Fonteyne as Class II directors, ratified Deloitte & Touche LLP as the independent registered public accounting firm for fiscal year 2026, and approved, on a non-binding advisory basis, the compensation of the company’s named executive officers. These decisions were formally reported in an 8-K filing, detailing the vote counts for each proposal.

https://www.stocktitan.net/sec-filings/AMLX/8-k-amylyx-pharmaceuticals-inc-reports-material-event-e7b9ab2901a3.html

AMLX - PBH Franchise And Neurodegeneration Pipeline Will Support A Stronger Future Business Model

Amylyx Pharmaceuticals (AMLX) is positioned for future growth through its focus on post bariatric hypoglycemia (PBH) with avexitide, a condition with no FDA-approved therapies, and a neurodegeneration pipeline including treatments for ALS and Wolfram syndrome. Analysts forecast future revenues of $107.8 million by March 2029, with an estimated fair value of $22.20 per share based on a 2029 PE ratio of 159.0x, despite current unprofitability. Key risks include the success of the pivotal Phase III LUCIDITY trial for avexitide, commercial launch challenges, and the need for additional capital if development costs rise or programs face setbacks.

https://simplywall.st/narratives/3mv6xgdi-pbh-franchise-and-neurodegeneration-pipeline-will-support-a-stronger-future-business-model?bpId=4513312&link_type=cta_ai_narrative

Trending Today

ZCash ($ZEC) Crypto Forecast: Up 5.7% Today

Stellar ($XLM) Crypto Forecast: Down 5.6% Today

Bitcoin ($BTC) Crypto Forecast: Up 5.1% Today

NASDAQ-100 ($NDX) Index Forecast: Down 5.2% Today

Ethereum ($ETH) Crypto Forecast: Up 5.3% Today

Amylyx Pharmaceuticals Price History

21.04.2026 - AMLX Stock was up 5.5%

• The positive news of the peer-reviewed publication of Phase 2 trial data for AMX0035 in treating Wolfram syndrome likely fueled the bullish movement in AMLX stock. The results, showing stabilization or improvement in various health parameters, have increased investor confidence in the company's drug pipeline.
• The reaffirmation of a Buy recommendation by B of A Securities has further bolstered investor sentiment towards Amylyx Pharmaceuticals, suggesting optimism about the company's future performance.
• The filing of an amended Schedule 13G/A by Perceptive Life Sciences Master Fund, Ltd., reporting a significant passive stake in AMLX, may have also contributed to the bullish movement by signaling institutional investor interest and support in the company's potential growth prospects.

18.04.2026 - AMLX Stock was down 5.1%

• A bearish movement in AMLX stock today may be due to profit-taking by investors following a recent bullish trend.
• The positive announcement of Phase 2 trial results for AMX0035 in Wolfram syndrome might have already been factored into the stock price, resulting in limited upward momentum.
• Despite receiving a Buy recommendation from B of A Securities, it might not have been sufficient to override broader market sentiments or short-term trading strategies.
• Speculation surrounding the Phase 3 trial outcome for AVEXITIDE and a potential launch in 2027 could be fueling speculative actions, causing some investors to sell off their positions in the near term.

15.04.2026 - AMLX Stock was down 5.6%

• The upcoming Phase 3 AVEXITIDE trial results in the third quarter failed to offset the negative impact of Amylyx Pharmaceuticals' Q1 2026 earnings miss, resulting in a significant drop in the stock price.
• Despite the favorable prospects for AVEXITIDE and the company's robust financial standing, the earnings miss brought forth investor worries regarding the current financial performance.
• Differing viewpoints on the valuation of Amylyx Pharmaceuticals emerged, as a DCF analysis suggested undervaluation while the P/B ratio indicated overvaluation, likely playing a role in the bearish market behavior as investors reevaluate the stock's true value.
• The substantial valuation discrepancy between the stock price and analyst predictions, notwithstanding the positive advancements with AVEXITIDE and strategic investments in R&D, might have intensified the downward momentum on AMLX shares.

29.03.2026 - AMLX Stock was down 5.1%

• The downward movement in AMLX stock today might be due to profit-taking by investors following several price target upgrades by different financial institutions. It is possible that traders decided to sell to secure profits after positive changes were made to the price targets.
• Despite the positive outlook from analysts and the excitement surrounding the Phase 3 LUCIDITY study data for avexitide, the market response today could indicate a short-term decline in the stock price.
• The reduction in the Co-CEO and Director's 2025 compensation compared to the previous year may also play a role in the negative sentiment towards the stock, potentially raising concerns about internal stability or performance expectations within the company.

28.03.2026 - AMLX Stock was down 5.2%

• The bearish movement in AMLX stock today could be attributed to the significant decrease in compensation for both Co-CEOs and Directors, Justin Klee and Joshua Cohen, as revealed in the recent SEC DEF14A filings. This unexpected decrease in executive pay may have raised concerns among investors about the company's financial performance or future prospects.
• Investors might be reacting to the upcoming Q3 2025 earnings preview, anticipating potentially disappointing financial results. The market sentiment could be influenced by expectations set by analysts and insiders' activities.
• Insider trading activities, hedge fund movements, and analyst ratings could have also contributed to the negative market sentiment surrounding AMLX stock, leading to the bearish movement observed today.

28.03.2026 - AMLX Stock was down 5.1%

• An increased price target for AMLX was influenced by a reduced expense forecast, potentially boosting investor confidence initially.
• However, concerns arose over the reduced compensation of the Co-CEO and Director in 2025, prompting doubts about the company's financial well-being and future prospects, leading to the bearish market movement.
• The impending Q3 2025 earnings preview may also be contributing to investor unease and stock selling pressure.
• In summary, despite positive adjustments to the price target, the news about reduced executive compensation and the upcoming earnings report could have dampened optimism, resulting in the decline of AMLX stock.

05.05.2026 - AMLX Stock was up 6.0%

• Key proposals at the Annual Meeting of Stockholders, including the election of new directors and the ratification of the independent accounting firm, likely boosted investor confidence in the company's governance and strategic direction.
• Analysts' optimism about Amylyx Pharmaceuticals' growth prospects, particularly in the post bariatric hypoglycemia (PBH) and neurodegeneration pipeline, may have attracted investors looking for long-term opportunities in the pharmaceutical industry.
• Progress in the pivotal Phase III LUCIDITY trial for avexitide, alongside potential future revenues and a positive estimated fair value per share, could have contributed to the bullish sentiment surrounding AMLX stock today.

12.04.2026 - AMLX Stock was down 5.2%

• A Discounted Cash Flow (DCF) analysis suggests AMLX is significantly undervalued, but its Price-to-Book (P/B) ratio indicates overvaluation compared to industry peers.
• Despite positive developments like completing enrollment for a pivotal trial and initiating an Expanded Access Program, AMLX's stock is trading below consensus targets and fair value estimates, leading to a large valuation gap.
• Analysts have provided varied ratings on AMLX, reflecting differing outlooks on the company's stock performance.
• The overall bearish movement in the healthcare sector, as evidenced by other healthcare stocks experiencing significant decreases in the pre-market session, could have contributed to AMLX's downward trend today.

07.04.2026 - AMLX Stock was down 6.9%

• The decline in AMLX stock today could be linked to the anticipation of the company's first-quarter financial results, which are projected to show a per-share loss and no revenue. This financial performance may have disappointed investors.
• Furthermore, the market's reaction to the news about the upcoming Phase 3 LUCIDITY trial data for avexitide, crucial for the company's future valuation and cash position, may have added to the negative sentiment.
• Amylyx Pharmaceuticals' involvement in investor conferences could have also impacted market sentiment, as investors may be waiting for insights or updates from these events before making significant decisions regarding the stock.
• Overall, factors such as financial performance expectations, forthcoming trial data, and participation in investor conferences likely contributed to the bearish movement in AMLX stock today.

14.03.2026 - AMLX Stock was up 5.3%

• The bullish movement in AMLX stock could be attributed to the selection of AMX0318 as a new development candidate, indicating progress in the company's pipeline for treating neurodegenerative diseases.
• The upcoming presentation at the 25th Annual Needham Virtual Healthcare Conference might have generated positive investor sentiment, as it provides a platform for the company to showcase its innovative therapies and potential market opportunities.
• Despite the investigation into potential breaches of fiduciary duties by insiders, investors seem optimistic about the company's future prospects, possibly due to the focus on addressing diseases with high unmet needs and the positive market analysis reports.
• Overall, the combination of positive corporate developments, upcoming conference presentation, and market analysis highlighting growth potential could have fueled the bullish momentum in AMLX stock today.

17.03.2026 - AMLX Stock was up 5.4%

• Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) received a "Moderate Buy" recommendation from brokerages, indicating positive sentiment towards the stock.
• The company reported quarterly earnings that slightly beat analyst estimates, contributing to the bullish movement in the stock.
• Insider transactions, such as recent sales by the CEO, and adjustments in holdings by institutional investors may have influenced market confidence in the company's future prospects, driving the bullish movement in the stock.

02.05.2026 - AMLX Stock was down 5.0%

• The recent downward trend in AMLX's stock may be linked to investors taking profits following a substantial price surge in the past year.
• While news of insider purchasing by director Karen Firestone was positive, market response may have been negative due to concerns about upcoming commercial launch obstacles and the requirement for additional capital for pipeline development.
• Uncertainties surrounding the success of the pivotal Phase III LUCIDITY trial for avexitide, a significant pipeline candidate, might also have contributed to the stock's decline.
• In conclusion, despite AMLX's strong long-term outlook with its innovative pipeline, short-term market sentiment and uncertainties could have influenced the current bearish movement.